SCHEMBL5788024

SCHEMBL5788024

CCc1ccc(C(=O)O)c(O)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SELL P14151 1/20 0.56
SELP P16109 1/20 0.56
GABRA1 P14867 3/20 0.48
GABRB2 P47870 3/20 0.48
ALDH1A1 P00352 4/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HMGB1 P09429 2/20 0.43
GABRP O00591 2/20 0.43
GABRD O14764 2/20 0.43
GABRB1 P18505 2/20 0.43
GABRG2 P18507 2/20 0.43
GABRB3 P28472 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRA3 P34903 2/20 0.43
GABRA2 P47869 2/20 0.43
GABRA4 P48169 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5788972 0.86 PRKCI (0.51) SELLSELPALDH1A1HPGDKDM4E
SCHEMBL9328643 0.84 SELL (0.58) SELLSELPALDH1A1HPGDKDM4E
SCHEMBL6683046 0.83 SELL (0.47) SELLSELPGABRA1GABRB2ALDH1A1
SCHEMBL7728985 0.82 GABRA1 (0.43) SELLSELPGABRA1GABRB2ALDH1A1
SCHEMBL28750906 0.82 CLCN2 (0.48) SELLSELPGABRA1GABRB2ALDH1A1
SCHEMBL7521299 0.81 PPARA (0.54)
SCHEMBL29695710 0.81 HMGB1 (0.65) SELLSELPGABRA1GABRB2ALDH1A1
SCHEMBL39623 0.81 HMGB1 (0.65) SELLSELPGABRA1GABRB2ALDH1A1
SCHEMBL29860525 0.81 SELL (0.79) SELLSELPALDH1A1HPGDKDM4E
SCHEMBL45861 0.81 GABRA1 (0.68) GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1041448-B1 Method for decoloring TOSHIBA KK (JP) 2006-06-07 EP claimed
CN-115281218-A Application of trichoderma fermentation liquor extract 贵州省生物技术研究所(贵州省生物技术重点实验室、贵州省马铃薯研究所、贵州省食品加工研究所) 2022-11-04 CN disclosed
EP-3645707-A1 METHOD FOR PRODUCING ERYTHROID PROGENITOR CELLS Etablissement Français du Sang (FR) 2020-05-06 EP disclosed
US-9079989-B2 Charge control resin and manufacturing method of the same ORIENT CHEMICAL INDUSTRIES CO., LTD. (JP) 2015-07-14 US disclosed
US-20150025213-A1 CHARGE CONTROL RESIN AND MANUFACTURING METHOD OF THE SAME ORIENT CHEMICAL INDUSTRIES CO., LTD. (JP) 2015-01-22 US disclosed
US-8883946-B2 Charge control resin and manufacturing method of the same ORIENT CHEMICAL INDUSTRIES CO., LTD. (JP) 2014-11-11 US disclosed
US-20140080989-A1 CHARGE CONTROL RESIN AND MANUFACTURING METHOD OF THE SAME ORIENT CHEMICAL INDUSTRIES CO., LTD. (JP) 2014-03-20 US disclosed
WO-2013187971-A2 MACROCYCLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-12-19 WO disclosed
CN-102321033-B Preparation method of tarceva JIANGSU HUIFENG AGROCHEMICAL CO LTD 2013-10-09 CN disclosed
CN-102321033-A Preparation method of tarceva JIANGSU HUIFENG AGROCHEMICAL CO LTD 2012-01-18 CN disclosed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed
EP-0604494-B1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1999-07-28 EP disclosed
US-5580885-A FOR TREATMENT OF GASTROINTESTINAL, CARDIOVASCULAR OR NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 1996-12-03 US disclosed
EP-0604494-A1 5-HT 4? RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-07-06 EP disclosed
WO-1993005038-A1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1993-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 SELL 3070/4885SELP 2754/4885GABRA1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.